胆红素:在阿尔茨海默氏症治疗中改变游戏规则? 揭示了它的神经保护和疾病修饰潜力
Ramandeep Kaur Sidhu1, Yukti Mittal1, Khadga Raj Aran2
1Department of Pharmacy Practice, ISF College of Pharmacy, Moga, 142001, Punjab, India.
Metabolic brain disease
|June 16, 2025
概括
胆红素通过减少氧化应激和神经炎症,对阿尔茨海默病 (AD) 产生神经保护作用. 然而,它的治疗用途需要谨慎的剂量,因为在更高水平的潜在毒性.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是粉样β斑块,神经纤维状,氧化应激和神经炎症,导致认知能力下降.
- 血红素是一种血红素代谢的副产品,是一种强大的内源性抗氧化剂,具有证明的神经保护能力.
研究的目的:
- 探索胆红素在阿尔茨海默病 (AD) 中的多方面的作用.
- 突出比利鲁宾在缓解AD病理方面的潜力,包括氧化应激,神经炎症和蛋白质聚合.
主要方法:
- 关于胆红素抗氧化和抗炎机制的现有文献的综述.
- 分析胆红素对粉样β (Aβ) 纤维化和高酸化的影响.
- 在AD的背景下检查 bilirubin 对突触和线粒体功能的影响.
主要成果:
- 胆红素通过胆红素-胆红素氧化还原循环有效地清除活性氧物种 (ROS),增强细胞防御能力.
- 胆红素调节关键的炎症通路 (NF-κB,TLR4) 以减少促炎细胞因子的释放.
- 胆红素促进Aβ清除,并通过影响酶和酸酶活性来抑制病理,从而保持神经元的完整性.
结论:
- 比利鲁通过解决多种病理特征,对阿尔茨海默病具有显著的治疗潜力.
- 关于阿尔茨海默病患者胆红素水平的相互矛盾的报告需要进一步研究最佳治疗度和剂量策略.
- 克服血脑屏障 (BBB) 透性和标准化胆红素评估等挑战对于临床翻译至关重要.
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686
The Blood-brain Barrier
49.0K
Overview
49.0K


